The effects of novel, bioresorbable scaffolds on coronary vascular pathophysiology

Journal of Cardiovascular Translational Research

Volumn 7, Issue 4, 2014, Pages 413-425

  Lipinski, Michael J ^a   Escarcega, Ricardo O ^a   Lhermusier, Thibault ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Bioresorbable scaffold; Percutaneous coronary intervention; Smooth muscle cells

Indexed keywords

ARTERY INTIMA PROLIFERATION; ARTICLE; BARE METAL STENT; BIORESORBABLE SCAFFOLD; BLOOD VESSEL FUNCTION; BLOOD VESSEL REACTIVITY; CORONARY ARTERY DISEASE; CORONARY VESSEL MALFORMATION; DRUG ELUTING STENT; HUMAN; INTERMETHOD COMPARISON; METAL IMPLANTATION; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; STENT THROMBOSIS; VESSEL ANGULATION; VESSEL RECOIL; VESSEL REMODELING; ANIMAL; BIODEGRADABLE IMPLANT; CORONARY BLOOD VESSEL; PROSTHESIS; STENT; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; ANIMALS; CORONARY ARTERY DISEASE; CORONARY VESSELS; DRUG-ELUTING STENTS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; STENTS; TREATMENT OUTCOME;

EID: 84903648922     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-014-9571-7     Document Type: Article

References (63)

1. Mintz, G. S.; Kent, K. M.; Pichard, A. D.; Satler, L. F.; Popma, J. J.; & Leon, M. B. (1997). Contribution of inadequate arterial remodeling to the development of focal coronary artery stenoses. An intravascular ultrasound study. Circulation, 95, 1791-1798.
2. Costa, M. A.; & Simon, D. I. (2005). Molecular basis of restenosis and drug-eluting stents. Circulation, 111, 2257-2273.
3. Holmes, D. R.; Jr.; & Vlietstra, R. E. (1989). Balloon angioplasty in acute and chronic coronary artery disease. JAMA, 261, 2109-2115.
4. Evans, D. J.; Jackman, L. E.; Chamberlain, J.; Crosdale, D. J.; Judge, H. M.; Jetha, K.; et al. (2009). Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis. Circulation, 119, 116-122.
5. Welt, F. G.; Edelman, E. R.; Simon, D. I.; & Rogers, C. (2000). Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 2553-2558.
6. Yamashita, A.; Shoji, K.; Tsuruda, T.; Furukoji, E.; Takahashi, M.; Nishihira, K.; et al. (2008). Medial and adventitial macrophages are associated with expansive atherosclerotic remodeling in rabbit femoral artery. Histology and Histopathology, 23, 127-136.
7. Toutouzas, K.; Colombo, A.; & Stefanadis, C. (2004). Inflammation and restenosis after percutaneous coronary interventions. European Heart Journal, 25, 1679-1687.
8. Giordano, A.; & Romano, A. (2011). Inhibition of human in-stent restenosis: a molecular view. Current Opinion in Pharmacology, 11, 372-377.
9. Fischman, D. L.; Leon, M. B.; Baim, D. S.; Schatz, R. A.; Savage, M. P.; Penn, I.; et al. (1994). A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. New England Journal of Medicine, 331, 496-501.
10. Roukoz, H.; Bavry, A. A.; Sarkees, M. L.; Mood, G. R.; Kumbhani, D. J.; Rabbat, M. G.; et al. (2009). Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. American Journal of Medicine, 122(581), e581-510.
11. Cutlip, D. E. (2000). Stent thrombosis: historical perspectives and current trends. Journal of Thrombosis and Thrombolysis, 10, 89-101.
12. Virmani, R.; Farb, A.; Guagliumi, G.; & Kolodgie, F. D. (2004). Drug-eluting stents: caution and concerns for long-term outcome. Coronary Artery Disease, 15, 313-318.
13. Zhou, W. R.; Zheng, Y. F.; Leeflang, M. A.; & Zhou, J. (2013). Mechanical property, biocorrosion and in vitro biocompatibility evaluations of Mg-Li-(Al)-(RE) alloys for future cardiovascular stent application. Acta Biomaterialia, 9, 8488-8498.
14. Bowen, P. K.; Drelich, J.; & Goldman, J. (2013). Zinc exhibits ideal physiological corrosion behavior for bioabsorbable stents. Advanced Materials, 25, 2577-2582.
15. Song, G. (2007). Control of biodegradation of biocompatible magnesium alloy. Corrosion Science, 49, 1696-1701.
16. Persaud-Sharma, D.; & McGoron, A. (2012). Biodegradable magnesium alloys: a review of material development and applications. Journal of Biomimetics, Biomaterials, and Tissue Engineering, 12, 25-39.
17. Ahamed, M.; Akhtar, M. J.; Siddiqui, M. A.; Ahmad, J.; Musarrat, J.; Al-Khedhairy, A. A.; et al. (2011). Oxidative stress mediated apoptosis induced by nickel ferrite nanoparticles in cultured A549 cells. Toxicology, 283, 101-108.
18. Cai, Y. L.; Zhang, J. J.; Zhang, S.; Venkatraman, S. S.; Zeng, X. T.; Du, H. J.; et al. (2010). Osteoblastic cell response on fluoridated hydroxyapatite coatings: the effect of magnesium incorporation. Biomedical Materials, 5, 054114.
19. Wang, B.; Huang, P.; Ou, C.; Li, K.; Yan, B.; & Lu, W. (2013). In vitro corrosion and cytocompatibility of ZK60 magnesium alloy coated with hydroxyapatite by a simple chemical conversion process for orthopedic applications. International Journal of Molecular Sciences, 14, 23614-23628.
20. Pierson, D.; Edick, J.; Tauscher, A.; Pokorney, E.; Bowen, P.; Gelbaugh, J.; et al. (2012). A simplified in vivo approach for evaluating the bioabsorbable behavior of candidate stent materials. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 100, 58-67.
21. Bowen, P. K.; Gelbaugh, J. A.; Mercier, P. J.; Goldman, J.; & Drelich, J. (2012). Tensile testing as a novel method for quantitatively evaluating bioabsorbable material degradation. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 100, 2101-2113.
22. Waksman, R.; Pakala, R.; Baffour, R.; Seabron, R.; Hellinga, D.; & Tio, F. O. (2008). Short-term effects of biocorrodible iron stents in porcine coronary arteries. Journal of Interventional Cardiology, 21, 15-20.
23. Wu, C.; Qiu, H.; Hu, X. Y.; Ruan, Y. M.; Tian, Y.; Chu, Y.; et al. (2013). Short-term safety and efficacy of the biodegradable iron stent in mini-swine coronary arteries. Chinese Medical Journal, 126, 4752-4757.
24. Waksman, R.; Pakala, R.; Kuchulakanti, P. K.; Baffour, R.; Hellinga, D.; Seabron, R.; et al. (2006). Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheterization and Cardiovascular Interventions, 68, 607-617. discussion 618-609.
25. Pinto Slottow, T. L.; Pakala, R.; Okabe, T.; Hellinga, D.; Lovec, R. J.; Tio, F. O.; et al. (2008). Optical coherence tomography and intravascular ultrasound imaging of bioabsorbable magnesium stent degradation in porcine coronary arteries. Cardiovascular Revascularization Medicine, 9, 248-254.
26. Erbel, R.; Di Mario, C.; Bartunek, J.; Bonnier, J.; de Bruyne, B.; Eberli, F. R.; et al. (2007). Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet, 369, 1869-1875.
27. Waksman, R.; Erbel, R.; Di Mario, C.; Bartunek, J.; de Bruyne, B.; Eberli, F. R.; et al. (2009). Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. JACC. Cardiovascular Interventions, 2, 312-320.
28. Li, H.; Zhong, H.; Xu, K.; Yang, K.; Liu, J.; Zhang, B.; et al. (2011). Enhanced efficacy of sirolimus-eluting bioabsorbable magnesium alloy stents in the prevention of restenosis. Journal of Endovascular Therapy, 18, 407-415.
29. Haude, M.; Erbel, R.; Erne, P.; Verheye, S.; Degen, H.; Bose, D.; et al. (2013). Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet, 381, 836-844.
30. Virmani, R. (2014). Biodegradable scaffolds: insight from the preclinical trials. Washington, DC: Paper presented at Cardiovascular Research Technologies 2014.
31. Maeng, M.; Jensen, L. O.; Falk, E.; Andersen, H. R.; & Thuesen, L. (2009). Negative vascular remodelling after implantation of bioabsorbable magnesium alloy stents in porcine coronary arteries: a randomised comparison with bare-metal and sirolimus-eluting stents. Heart, 95, 241-246.
32. Soucy, N. V.; Feygin, J. M.; Tunstall, R.; Casey, M. A.; Pennington, D. E.; Huibregtse, B. A.; et al. (2010). Strut tissue coverage and endothelial cell coverage: a comparison between bare metal stent platforms and platinum chromium stents with and without everolimus-eluting coating. EuroIntervention, 6, 630-637.
33. Finn, A. V.; Joner, M.; Nakazawa, G.; Kolodgie, F.; Newell, J.; John, M. C.; et al. (2007). Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation, 115, 2435-2441.
34. Sternberg, K.; Gratz, M.; Koeck, K.; Mostertz, J.; Begunk, R.; Loebler, M.; et al. (2011). Magnesium used in bioabsorbable stents controls smooth muscle cell proliferation and stimulates endothelial cells in vitro. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 100, 41-50.
35. Ghimire, G.; Spiro, J.; Kharbanda, R.; Roughton, M.; Barlis, P.; Mason, M.; et al. (2009). Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents. EuroIntervention, 4, 481-484.
36. Waksman, R.; Prati, F.; Bruining, N.; Haude, M.; Bose, D.; Kitabata, H.; et al. (2013). Serial observation of drug-eluting absorbable metal scaffold: multi-imaging modality assessment. Circulation. Cardiovascular Interventions, 6, 644-653.
37. Gyongyosi, M.; Yang, P.; Khorsand, A.; & Glogar, D. (2000). Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events. Austrian Wiktor Stent Study Group and European Paragon Stent Investigators. Journal of the American College of Cardiology, 35, 1580-1589.
38. Oberhauser, J. P.; Hossainy, S.; & Rapoza, R. J. (2009). Design principles and performance of bioresorbable polymeric vascular scaffolds. EuroIntervention, 5(Suppl F), F15-F22.
39. Nishio, S.; Kosuga, K.; Igaki, K.; Okada, M.; Kyo, E.; Tsuji, T.; et al. (2012). Long-term (>10 years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation, 125, 2343-2353.
40. Ormiston, J. A.; Serruys, P. W.; Regar, E.; Dudek, D.; Thuesen, L.; Webster, M. W.; et al. (2008). A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet, 371, 899-907.
41. Serruys, P. W.; Ormiston, J. A.; Onuma, Y.; Regar, E.; Gonzalo, N.; Garcia-Garcia, H. M.; et al. (2009). A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet, 373, 897-910.
42. Serruys, P. W.; Onuma, Y.; Dudek, D.; Smits, P. C.; Koolen, J.; Chevalier, B.; et al. (2011). Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. Journal of the American College of Cardiology, 58, 1578-1588.
43. Onuma, Y.; Serruys, P. W.; Perkins, L. E.; Okamura, T.; Gonzalo, N.; Garcia-Garcia, H. M.; et al. (2010). Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation, 122, 2288-2300.
44. Verheye, S.; Ormiston, J. A.; Stewart, J.; Webster, M.; Sanidas, E.; Costa, R.; et al. (2014). A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC. Cardiovascular Interventions, 7, 89-99.
45. Durand, E.; Lemitre, M.; Couty, L.; Sharkawi, T.; Brasselet, C.; Vert, M.; et al. (2012). Adjusting a polymer formulation for an optimal bioresorbable stent: a 6-month follow-up study. EuroIntervention, 8, 242-249.
46. Durand, E.; Sharkawi, T.; Leclerc, G.; Raveleau, M.; van der Leest, M.; Vert, M.; & Lafont, A. (epub 2013). Head-to-head comparison of a drug-free early programmed dismantling polylactic acid bioresorbable scaffold and a metallic stent in the porcine coronary artery: six-month angiography and optical coherence tomographic follow-up study. Circulation: Cardiovascular Intervention
47. Granada, J. F. (2014). The Amaranth PLLA based bioresorbable scaffold (ARBS): Experimental and early human results. Washington, DC: Paper presented at Cardiovascular Research Technologies 2014.
48. Onuma, Y.; Serruys, P. W.; Gomez, J.; de Bruyne, B.; Dudek, D.; Thuesen, L.; et al. (2011). Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheterization and Cardiovascular Interventions, 78, 3-12.
49. Gomez-Lara, J.; Brugaletta, S.; Farooq, V.; Onuma, Y.; Diletti, R.; Windecker, S.; et al. (2011). Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. JACC. Cardiovascular Interventions, 4, 1271-1280.
50. Ormiston, J. A.; Serruys, P. W.; Onuma, Y.; van Geuns, R. J.; de Bruyne, B.; Dudek, D.; et al. (2012). First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circulation. Cardiovascular Interventions, 5, 620-632.
51. Pollman, M. J. (2009). Engineering a bioresorbable stent: REVA programme update. EuroIntervention, 5(Suppl F), F54-F57.
52. Costa, R. A. REVA ReZolve Clinical Program Update. Paper presented at TCT, 2012.
53. Jabara, R. Poly-anhydride based on salicylic acid and adipic acid anhydride. Paper presented at PCR, 2009.
54. Lafont, A. (2014). The PDLLA ART FIH experiences: is the drug necessary? Washington, DC: Paper presented at Cardiovascular Research Technologies 2014.
55. Farooq, V.; Serruys, P. W.; Heo, J. H.; Gogas, B. D.; Onuma, Y.; Perkins, L. E.; et al. (2013). Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice. JACC. Cardiovascular Interventions, 6, 523-532.
56. Brugaletta, S.; Radu, M. D.; Garcia-Garcia, H. M.; Heo, J. H.; Farooq, V.; Girasis, C.; et al. (2012). Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis, 221, 106-112.
57. Brugaletta, S.; Gomez-Lara, J.; Garcia-Garcia, H. M.; Heo, J. H.; Farooq, V.; van Geuns, R. J.; et al. (2012). Analysis of 1 year virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. International Journal of Cardiovascular Imaging, 28, 1307-1314.
58. Brugaletta, S.; Heo, J. H.; Garcia-Garcia, H. M.; Farooq, V.; van Geuns, R. J.; de Bruyne, B.; et al. (2012). Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? European Heart Journal, 33, 1325-1333.
59. Jabara, R.; Pendyala, L.; Geva, S.; Chen, J.; Chronos, N.; & Robinson, K. (2009). Novel fully bioabsorbable salicylate-based sirolimus-eluting stent. EuroIntervention, 5(Suppl F), F58-F64.
60. Nieman, K.; Serruys, P. W.; Onuma, Y.; van Geuns, R. J.; Garcia-Garcia, H. M.; de Bruyne, B.; et al. (2013). Multislice computed tomography angiography for noninvasive assessment of the 18-month performance of a novel radiolucent bioresorbable vascular scaffolding device: the ABSORB trial (a clinical evaluation of the bioabsorbable everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). Journal of the American College of Cardiology, 62, 1813-1814.
61. Ishibashi, Y.; Onuma, Y.; Muramatsu, T.; Nakatani, S.; Iqbal, J.; Garcia-Garcia, H. M.; Bartorelli, A. L.; Whitbourn, R.; Abizaid, A.; & Serruys, P. W. (2014). Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial. EuroIntervention.
62. Diletti, R.; Serruys, P. W.; Farooq, V.; Sudhir, K.; Dorange, C.; Miquel-Hebert, K.; et al. (2012). ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. American Heart Journal, 164, 654-663.
63. Waksman, R. (2014). Biodegradable scaffolds: Will they change our practice? Washington, DC: Paper presented at Cardiovascular Research Technologies 2014.